Effect of biological treatment in uncontrolled severe chronic rhinosinusitis with nasal polyps in Belgium: a multicentre real-world data study
Both mepolizumab and omalizumab significantly improved patient-reported outcomes after 24-weeks, with major effects already observed at 12 weeks. Follow-up beyond 24-weeks might reveal additional effects on both control and remission.
Authors
- Kato Speleman
- Florence Rogister (ORCID: https://orcid.org/0000-0002-9483-6495)
- Laura Van Gerven (ORCID: https://orcid.org/0000-0002-5325-7956)
- Peter W. Hellings (ORCID: https://orcid.org/0000-0001-6898-688X)
- Stijn Halewyck
- Karen H. Martens
- W.A.J.G. Lemmens (ORCID: https://orcid.org/0000-0002-7159-0541)
- Anneclaire V. Vroegop (ORCID: https://orcid.org/0000-0001-7538-2021)
- B. Verhaeghe
- Olivier M. Vanderveken (ORCID: https://orcid.org/0000-0002-4088-4213)
- A-S Viskens
- Elien Borgers
- Valérie Hox (ORCID: https://orcid.org/0000-0003-2390-294X)
- Mark Jorissen
- Laura Bollens
Institutions
- Cliniques Universitaires Saint-Luc (BE)
- University of Antwerp (BE)
- Universitair Ziekenhuis Leuven (BE)
- Ghent University (BE)
- Onze Lieve Vrouwziekenhuis Hospital (BE)
- Antwerp University Hospital (BE)
- AZ Sint-Jan (BE)
- Centre Hospitalier Universitaire de Liège (BE)
- Ziekenhuis Oost-Limburg (BE)
- KU Leuven (BE)
Publication Details
- Journal
- Rhinology Journal
- Published
- 2025-04-01
- DOI
- https://doi.org/10.4193/rhin24.509
- Citations
- 2
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 3.70